Skip to main content
. Author manuscript; available in PMC: 2018 Oct 15.
Published in final edited form as: Cancer Res. 2017 Aug 22;77(20):5491–5502. doi: 10.1158/0008-5472.CAN-17-0925

Figure 6.

Figure 6

Selective toxicity of TSC-LAM patient SMCs by dual targeting of mTORC1 and autophagy signaling. (A) Representative western blots of LC3B-I and LC3B-II levels in control (120ls-SMCs) and P6-derived SMC lines to depict LC3B-II accumulation in vehicle versus +bafilomycin A1 conditions, and the corresponding response to mTOR inhibitors torin-1 and rapamycin. (B) Basal levels of LC3B-II, based on densitometry quantification of western blots and normalized to β-actin levels, in SMC lines under vehicle, torin-1 or rapamycin treatment. Statistics are relative to vehicle. (C) % of cells positive for propidium iodide (PI) relative to vehicle for each cell line, following a 24 hr treatment with 2.5 µM chloroquine (CQ), 20 nM rapamycin, or both. Measurements were collected via flow cytometry. P values of <0.05 (*) and <0.001 (***), obtained by t-test, are indicated. Three biological replicates were performed for each experiment and treatment condition.